Research programme: anticancer DARPin therapeutics - Molecular Partners

Drug Profile

Research programme: anticancer DARPin therapeutics - Molecular Partners

Alternative Names: MP 0274; Multispecific-DARPins - Molecular Partners; PD1-VEGF-targeting DARPin®

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Molecular Partners AG
  • Class Antineoplastics; Proteins
  • Mechanism of Action Apoptosis stimulants; ERBB 2 receptor antagonists; PDCD 1 protein inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Apr 2017 Preclinical data in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 23 Mar 2017 Molecular Partners plans a phase I trial for Neoplasms (NCT03084926)
  • 06 Dec 2016 Pharmacokinetics and pharmacodynamics data from preclinical studies in Cancer presented at the 39th Annual San Antonio Breast Cancer Symposium (SABCS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top